Alberto Bardelli

From 1999 to 2004, Bardelli has been a postdoctoral researcher at the Johns Hopkins University School of Medicine and the Howard Hughes Medical Institute, Baltimore (MD/USA), in the group led by Bert Vogelstein.

In 2004, he returned to Italy as director of a research unit dedicated to the study of tumour genomes at the Candiolo Cancer Institute and Dept.

[9][10][11] His group used several approaches in their work, including genetic analysis of clinical samples, a large collection of CRC cellular models,[12] patient-derived xenografts (xenopatients), and liquid biopsies.

These findings have been rapidly translated into clinically applicable predictive biomarkers, which represent the first example of personalized medicine for colorectal tumours and are used to select patients for therapy.

His studies are built on an unconventional approach that an increased dynamic and mutational load in CRC cells can rouse an otherwise slack immune response, a vital requisite for effective immunosurveillance.

[17] Bardelli's studies have been reported in high peer-reviewed scientific journals as Cancer Cell, Nature, JAMA, and Lancet Oncology.